Testing SYS6051 for Advanced Solid Tumors
Part of Cancer clinical trials.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer (confirmed by biopsy or tissue sample) that can be seen on imaging
- You are 18 years or older and in good enough health to handle treatment (ECOG score 0–1, meaning you can do most normal activities)
- Your organs (liver, kidneys, heart, lungs) are working well enough for the study
- You are expected to live at least 3 months
- If you can have children, you agree to use reliable birth control during and for 4–7 months after treatment
- You have no active bleeding problems, lung disease, heart disease, or untreated brain/spinal cord tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
This clinical trial tests a new investigational drug (SYS6010) combined with another drug (SYH2051) or given alone, compared to standard chemotherapy, for advanced breast cancer and other solid tumors that have a specific protein called EGFR. The goal is to see if this treatment can help shrink tumors or slow their growth.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This trial tests whether adding a new drug called SYS6006 to an existing cancer treatment (enlonstobart) works better than enlonstobart alone for advanced solid tumors that cannot be surgically removed. The goal is to see if the combination helps shrink tumors and improve survival.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.